Augmented release of serotonin by adenosine A2a receptor activation and desensitization by CGS 21680 in the rat nucleus tractus solitarius.
Rat dorsomedial medullary brain segments containing primarily nucleus tractus solitarius (NTS) were employed for slice superfusion studies of electrically evoked [3H]serotonin ([3H]5-HT) release. Individual slices loaded with [3H]5-HT were stimulated two times, S1 and S2, at 3 Hz, 25 mA, 2 ms pulses for 1 min. Control NTS slices had a S2/S1 ratio of 0.94 (+/- 0.02). Superfusion of tissue slices with 0.1 nM to 100 nM 2-p-(2-carboxyethyl)-phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680), a selective adenosine A2a receptor agonist, for 5 min prior to the S2 stimulus produced a significant concentration-dependent increase in the S2/S1 fractional release ratio which was maximal (37.2% increase, P < 0.01) at 1.0 nM. However, superfusion of tissue slices with CGS 21680 over the same concentration range for 20 min prior to the S2 stimulus did not significantly alter the S2/S1 ratio from control release ratios. The augmented release of [3H]5-HT mediated by 1.0 nM CGS 21680 with 5 min tissue exposure was abolished by 1.0 nM 9-chloro-2-(2-furanyl)-5, 6-dihydro-[1,2,4]-triazolo[1,5-c]quinazolin-5-imine (CGS 15943) as well as by 100 nM 8-(3-chlorostyryl)caffeine (CSC), both A2a receptor antagonists, but not by 1.0 nM 8-cyclopentyl-1,3,-dipropylxanthine (DPCPX), the A1 receptor antagonist. These results indicate that CGS 21680 augmented the evoked release of [3H]5-HT in the NTS by way of activation of presynaptic adenosine A2a receptors. It was also apparent that this population of adenosine A2a receptors in the NTS desensitized within 20 min since the augmenting action of CGS 21680 on evoked transmitter release was not evident at the longer time interval.
Department of Physiology, Wayne State University School of Medicine, Detroit, MI 48201, USA.
R A
RA
Barraco
C C
CC
Helfman
G F
GF
Anderson
D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D066298:In Vitro Techniques; D007700:Kinetics; D008297:Male; D010627:Phenethylamines / Q000494:pharmacology*; D058906:Purinergic P1 Receptor Agonists; D011799:Quinazolines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018047:Receptors, Purinergic P1 / Q000187:drug effects / Q000502:physiology*; D012701:Serotonin / Q000378:metabolism*; D017552:Solitary Nucleus / Q000187:drug effects / Q000502:physiology*; D014230:Triazoles / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology
D010627:Phenethylamines; D058906:Purinergic P1 Receptor Agonists; D011799:Quinazolines; D018047:Receptors, Purinergic P1; D014230:Triazoles; D014970:Xanthines; C061282:2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine; D012701:Serotonin; C051360:1,3-dipropyl-8-cyclopentylxanthine; D000241:Adenosine; C052410:9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine